
    
      Subjects meeting all inclusion and exclusion criteria will receive lenalidomide

      lenalidomide will be administered at 10 mg (two 5 mg capsules) once daily on Days 1-21, every
      4 weeks.

      Bone marrow aspirate (baseline and during the course of the study at week 8, 16, 32, 52 and
      when clinically indicated/for assessment of disease progression) evaluations

      Subjects may participate in the study for up to 52 weeks ( in patients still responding after
      52 weeks, the drug wil continue to be supplied).
    
  